Program
verekitug
Also written as “Verekitug (UPB-101)”, “Verekitug” and “UPB-101”.
Its studies are mostly in Asthma · Nasal Polyps · Pulmonary Disease, Chronic Obstructive, led by Upstream Bio.
Furthest: phase 2, since Dec 1, 20236 company-led studies, 2 open or runningNext primary completion: Sep 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Upstream Bio | 62 open or running | phase 2since Dec 1, 2023 | Jun 29, 2022 | Sep 2027phase 2 · NCT06966479 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 29, 2022First study: phase 1 study in AsthmaFirst studyNCT05448651 · 32 enrolled · United Kingdom
- Dec 7, 2022Phase 1 study in HealthyNCT05653479 · 32 enrolled · United Kingdom
- Dec 1, 20232 phase 2 studiesNCT06164704, NCT06196879
- May 9, 20252 phase 2 studiesNCT06981078, NCT06966479
Ahead
- Sep 2027Primary completion: phase 2 study in AsthmaNCT06966479
- Oct 2027Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT06981078
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06981078Pulmonary Disease, Chronic Obstructive · United States, Argentina, Bulgaria and more | 2 | Active, not recruiting | Oct 2027 | 666 |
| NCT06966479Asthma · United States, Argentina, Bulgaria and more | 2 | Active, not recruiting | Sep 2027 | 396 |
| NCT06196879Asthma · United States, Argentina, Bulgaria and more | 2 | Completed | Dec 16, 2025 | 479 |
| NCT06164704Nasal Polyps · United States, Czechia, Germany and more | 2 | Completed | Jul 7, 2025 | 81 |
| NCT05653479Healthy · United Kingdom | 1 | Completed | Apr 7, 2023 | 32 |
| NCT05448651Asthma · United Kingdom | 1 | Completed | Aug 15, 2023 | 32 |
How it is read
Names in the registry
- “Verekitug (UPB-101)”, 2 entries
- “Verekitug”, 2 entries
- “UPB-101”, 2 entries
Conditions, from the studies’ own filings
- Asthma, 3 studies
- Nasal Polyps, 1 study
- Pulmonary Disease, Chronic Obstructive, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.